Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Support for colorectal cancer screening with sigmoidoscopy

Early results of a randomized controlled trial in this week's issue of the Lancet suggest that a single flexible sigmoidoscopy screening program, offered at around age 60 years, could lower the incidence and mortality of colorectal cancer.

News image

fiogf49gjkf04

Around 16,000 people die from colorectal cancer in the UK every year, with annual health-care costs for treatment of the disease estimated at £300 million.

Survival rates exceed 90% if the disease is detected at an early stage; population screening is feasible as most invasive tumors develop slowly from non-cancerous polyps.

In the UK, flexible sigmoidoscopy is judged a more suitable tool for population screening than colonoscopy (advocated in the USA), because it is safer, cheaper, quicker, and more convenient. In addition, uptake rates are much higher.

Two thirds of adenomas and cancers are located in the rectum and sigmoid colon, which is within reach of the flexible sigmoidoscope, and the procedure takes only 5 minutes.

Wendy Atkin and colleagues from Cancer Research UK led the trial.

Men and women aged 55-64 years from 14 UK centers were randomly assigned screening or control (ratio 1:2). The control group was not contacted.

Small polyps were removed during screening, and individuals were referred for colonoscopy if high-risk polyps were found.

Around 170,000 individuals were randomized. Attendance among those assigned screening was 71%.

Some 2131 (5%) patients were classified as high-risk and referred for colonoscopy; 38,525 (95%) with no polyps or only low-risk polyps detected were discharged.

There was 1 perforation in 40,000 flexible sigmoidoscopy examinations, compared with 4 perforations among 2377 patients given colonoscopy.

Perforation was 100-times more likely with colonoscopy than sigmoidoscopy.
Lancet

An average of 48 people were screened, and 2 or 3 colonoscopy referrals generated, per center each week.

In an accompanying Commentary, David Ransohoff from the University of North Carolina, USA, comments, "The UK investigators raise provocative questions about the approach of tailoring not only work-up and surveillance, but also screening itself.

"For example, by suggesting once-in-a-lifetime screening sigmoidoscopy, or by suggesting that some subgroups have such a low risk of proximal colorectal cancer, that sigmoidoscopy alone may be a quite adequate test."

"Implementation of a tailored approach, by adjusting intensity of screening or surveillance to a person's risk, requires consideration of three points.

"These are the individual's absolute risk of colorectal cancer, the degree to which each screening or surveillance strategy reduces that risk, and quantitative definition of the goals of screening (i.e. what level of absolute risk is high enough to justify the effort of reduction)," he adds.

"By contrast, a one-size-fits-all approach to screening and surveillance may be easier to implement, but less efficient.

"In some cases - for example, when people with very low risk of subsequent colorectal cancer undergo potentially hazardous surveillance procedures such as colonoscopy - such an approach may even be harmful.

"A tailored approach, based on a quantitative definition of the goals of screening and surveillance, deserves increased consideration."

"Further reports from the UK trial and its USA counterpart will help guide the design and implementation of screening programs to reduce deaths from colorectal cancer, " he concludes.

Lancet 2002; 359(9314): 1266, 1291
12 April 2002

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us